LiteFold goes GA: drug discovery needs experiment-driven hill climbing, not isolated AI predictions
dejavucoder · x · 2026-11-02
After a year of building platforms, training foundation models, and achieving wet-lab validation with biotech partners, the LiteFold team announced general availability of LiteFold.
Their core thesis: the future of drug discovery isn't isolated AI predictions, but continuous engineering and optimization driven by experimental evidence — "Hill Climb Biology." The author argues next breakthroughs will come from small teams of 5–10 scientists, given the sheer number of diseases, targets, and molecules to engineer. LiteFold's pitch: own your research, control your data, use the best models, and keep improving from experiments.
Related event: LiteFold Launches Globally with Experiment-Driven Protein Design(2 posts)→
More from AGI Musings
- dhh: agent era ends tech talent's immunity for being difficult, soft skills matter — bendee983 · 2026-11-02
- AI-era creativity debate: real-world inputs are the nonrenewable 'primary colors' LLMs burn through — GrantCuster · 2026-11-02
- Ex-OpenAI: Agentic payments will be services' fastest-growing revenue channel — virattt · 2026-11-02
- Agents browse a lot but pay little — data sellers say pay-per-request is booming — virattt · 2026-11-02
- Scott Alexander's AI superforecaster says Anthropic quitting lifts global-pause odds just 16%→19% — peterbhase · 2026-11-02
- Scott Alexander: AI superforecaster puts global-pause odds bump from Anthropic exit at 16%→19% — peterbhase · 2026-11-02